Tennessee lawmakers are weighing whether to fund clinical trials of ibogaine, a psychedelic compound advocates say could help veterans and others with PTSD and addiction.
The Helping Open Pathways to Effective (HOPE) Treatment Act was introduced in January and remains under consideration in both Senate and House committees. Advocates rallied for action on the proposal at the state Capitol Feb. 24.
Ibogaine, pronounced i-bow-gain, is illegal for use ...
Treatment-resistant depression (TRD) is currently considered one of the most significant challenges in psychiatry: Millions of patients do not respond adequately to existing medications, alongside heavy costs for healthcare systems and ongoing functional loss.
Against this backdrop, the Israeli biopharma company PsyRx is developing an innovative combination drug that seeks to address one of the main failure points of antidepressant treatments – the long time until a significant clinical effect ...
Happy Friday and welcome back to The Microdose, an independent journalism newsletter brought to you by the U.C. Berkeley Center for the Science of Psychedelics.
Compass announces promising yet modest results from second Phase 3 trial
On Tuesday, Compass Pathways announced results from COMP006, its second Phase 3 trial using ...
Ibogaine is a naturally occurring plant alkaloid and hallucinogen being explored in some contexts as a treatment for substance use disorders and …